Described herein are pharmaceutical compositions comprising therapeutically effective quantities of (i) a K.sub.ATP channel modulator; and (ii) a CB.sub.x modulator. Also described herein are methods of making and using these compositions.

Solvay Pharmaceuticals GmbH

Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators

Described is a novel combination therapy for diabetes mellitus type I and/or for obesity and its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, by administering a combination of at least one K.sub.ATP channel opener as a first active agent and at least one CB.sub.1 cannabinoid receptor antagonist as a second active agent. The invention is further directed to such novel combination therapy wherein a dually acting compound with combined K.sub.ATP channel opening and CB.sub.1 antagonistic properties is used. The invention also relates to novel pharmaceutical compositions comprising K.sub.ATP channel openers and CB.sub.1 antagonists and the use of said pharmaceutical compositions in the treatment, delayed progression, delayed onset of and/or inhibition of diabetes mellitus type 1, and the prophylaxis and treatment, of obesity as well as the prophylaxis, treatment, delayed onset and/or inhbition of its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, in mammals and humans. The invention is further directed to such novel pharmaceutical compositions comprising a dually acting compound with combined K.sub.ATP channel opening and CB.sub.1 antagonistic properties.

Abbott Products GmbH

Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions

A dry consumable preparation and related methods are disclosed. The preparation has a bulking agent, and a cannabinoid and/or a cannabinoid extract containing one or more cannabinoids plated onto the bulking agent. The preparation also has an effervescence agent. The effervescence agent has sodium bicarbonate, potassium bicarbonate, and at least one acid, the at least one acid having at least one of citric acid, tartaric acid, or malic acid. The effervescence agent further has a ratio of sodium bicarbonate to potassium bicarbonate to the acid(s) that creates a chemical pH buffering system at a targeted pH range when the dry consumable preparation is added to a targeted amount of water.

potassium/hampor

Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators

Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions

Cannabinoid emulsion product and process for making the same

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen